c-Maf controls immune responses by regulating disease-specific gene networks and repressing IL-2 in CD4+ T cells

Leona Gabryšová¹, Marisol Alvarez-Martinez¹, Raphaëlle Luisier², Luke S. Cox¹, Jan Sodenkamp³, Caroline Hosking³, Damián Pérez-Mazliah³, Charlotte Whicher¹, Yashaswini Kannan⁴, Krzysztof Potempa¹, Xuemei Wu¹, Leena Bhaw⁵, Hagen Wende⁶, Michael H. Sieweke⁷,⁸, Greg Elgar⁵, Mark Wilson⁴, James Briscoe⁹, Vicki Metzis⁹, Jean Langhorne³, Nicholas M. Luscombe²,¹⁰ and Anne O’Garra¹,¹¹

¹The Francis Crick Institute, Laboratory of Immunoregulation and Infection, Midland Road, London, UK; ²The Francis Crick Institute, Computational Biology Laboratory, Midland Road, London, UK; ³The Francis Crick Institute, Malaria Laboratory, Midland Road, London, UK; ⁴The Francis Crick Institute, Helminth Immunology Laboratory, Midland Road, London, UK; ⁵The Francis Crick Institute, Advanced Sequencing Facility Laboratory, Midland Road, London, UK; ⁶Heidelberg University, Institute of Pharmacology, Heidelberg, Germany; ⁷Aix Marseille Univ, CNRS, INSERM, CIMAL, Marseille, France; ⁸Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtzgemeinschaft (MDC), Robert-Rössle-Strasse 10, 13125 Berlin, Germany; ⁹The Francis Crick Institute, Developmental Dynamics Laboratory, Midland Road, London, UK; ¹⁰UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, Gower Street, London, UK; ¹¹National Heart and Lung Institute, Imperial College London, London, UK.

Please address correspondence to:

* Anne O’Garra, ¹The Francis Crick Institute, Laboratory of Immunoregulation and Infection, 1 Midland Road, London; e-mail: anne.ogarra@crick.ac.uk.
Abstract

The transcription factor c-Maf induces the anti-inflammatory cytokine IL-10 in CD4$^+$ T cells in vitro. However, the global effects of c-Maf on diverse immune responses in vivo are unknown. Here we show that c-Maf regulates IL-10 production in CD4$^+$ T cells in T$_H$1 (malaria), T$_H$2 (allergy) and T$_H$17 (autoimmunity) disease models in vivo. Although CD4-targeted Maf-deficient mice showed greater pathology in T$_H$1 and T$_H$2 responses, T$_H$17-mediated pathology was reduced, with accompanying decreased T$_H$17 and increased Foxp3$^+$ regulatory T cells. Bivariate genomic footprinting elucidated the c-Maf transcription factor network, including enhanced NFAT activity, leading to the identification and validation of c-Maf as a negative regulator of IL-2. Decreased Rorc resulting from c-Maf deficiency was dependent on IL-2, explaining the in vivo observations. Thus, c-Maf is a positive and negative regulator of cytokine gene expression, with context-specific effects that allow each immune response to occur in a controlled yet effective manner.
**Introduction**

The immune response is under strict control to regulate the production of inflammatory mediators to control infection with minimum damage to the host. CD4$^+$ T cell subsets including T$_{H}1$, T$_{H}2$ and T$_{H}17$ cells are critical for eradication of specific pathogens$^1$, but if uncontrolled, can contribute to immune pathologies, either during infection or immunemediated diseases$^2,3$. A number of regulatory mechanisms are in place to control inappropriate or excessive immune responses, including the production of the anti-inflammatory cytokine IL-10 (ref. $^4$) and Foxp3-expressing CD4$^+$ regulatory (T$_{reg}$) cells$^5$. Although distinct molecular pathways direct the development of different effector and regulatory CD4$^+$ T cells, IL-10 is produced by all CD4$^+$ T cell subsets and is therefore not a subset-specific cytokine$^4$. Whether IL-10 production is regulated by lineage-specific mechanisms, or whether a common transcription factor (TF) controls IL-10 in all CD4$^+$ T cell subsets is unclear. Many TFs$^{6-20}$ have been shown to modulate Il10 gene expression including the activator protein (AP)-1 superfamily member c-Maf$^{7,16,19}$. c-Maf functions to control an array of biological processes including lens and bone development, apoptosis, oncogenesis, and the immune response$^{22}$. Although c-Maf has been shown to positively regulate Il10 gene expression in vitro$^{6,7,16,21}$, its effects on Il10 and global gene expression across different immune responses in vivo are unknown.

Here we report that c-Maf regulates IL-10 in vivo in CD4$^+$ T cells from T$_{H}1$ (malaria), T$_{H}2$ (allergy) and T$_{H}17$ (autoimmunity) disease models, but has context-specific effects on these immune responses, over and above effects on IL-10. Using genomic approaches, we found that Maf-deficient CD4$^+$ T cells showed significant changes in transcriptional activity, including enhanced NFAT activity, leading to the
identification and validation of c-Maf as a negative regulator of IL-2. This provided an explanation for the context-specific effects of c-Maf deficiency on the immune responses, which included decreased T\(h\)17 cells, increased Foxp3\(^{+}\) T\(_{reg}\) cells and reduced autoimmune pathology in vivo.

**Results**

**Maf and Il10 expression correlate in all T\(_{H}\) and T\(_{reg}\) cell subsets.** To identify candidate TFs regulating the expression of Il10 in different CD4\(^{+}\) T cell subsets, in vitro differentiated T\(_{H}\)1, T\(_{H}\)1+IL-27 (ref. 23), T\(_{H}\)2, T\(_{H}\)17, IL-10 only producing VitD3+Dex3 (ref. 24) T cells and ex vivo derived Foxp3\(^{+}\) T\(_{reg}\) cells were profiled by RNA-seq (Fig. 1a-d). We correlated the expression of TFs to Il10 mRNA across all T\(_{H}\) and T\(_{reg}\) cell subsets (Fig. 1e; Supplementary Table 1). Maf which was upregulated upon differentiation (Supplementary Fig. 1), was the strongest candidate for a positive regulator of Il10 (Fig. 1e and f) against other TFs previously associated with IL-10 (ref. 6-17,21,25) (Fig. 1e). In contrast, no correlation between Maf expression and the hallmark cytokines Ifng or Il4 was observed but, as expected, these effector cytokines showed tight correlation with expression of the T\(_{H}\)1 and T\(_{H}\)2 hallmark TFs, Tbx21 and Gata3, respectively (Fig. 1f). Thus, c-Maf may function as a common regulator of IL-10 in CD4\(^{+}\) T cells regardless of the T cell subset.

**c-Maf deficiency in CD4\(^{+}\) T cells affects susceptibility to disease in a context-specific manner.** Having identified c-Maf as the strongest candidate TF regulator of IL-10, we next sought to test whether c-Maf is a common regulator of IL-10 in vivo and to what
extent c-Maf affects the immune response and associated pathologies. To this end, we investigated the effect of CD4-targeted Maf deletion in mouse models of malaria (T\textsubscript{H}1), house dust mite (HDM) allergy (T\textsubscript{H}2) and experimental autoimmune encephalitis (EAE) (T\textsubscript{H}17), encapsulating a spectrum of immune responses (Fig. 2a-c). In the malaria model, Maf\textsuperscript{fl/fl} Cd4-cre mice showed increased acute-phase pathology, with significant weight loss and decline in temperature, but little to no effect on parasite load as compared to Maf\textsuperscript{fl/fl} control mice (Fig. 2d). Similarly, in the HDM allergy model, Maf\textsuperscript{fl/fl} Cd4-cre mice had increased total number of cells in the bronchoalveolar lavage, mostly consisting of eosinophils, and increased lung pathology characterised by greater mucus and inflammation scores as compared to Maf\textsuperscript{fl/fl} control mice (Fig. 2e). Maf\textsuperscript{fl/fl} Cd4-cre mice showed reduced pathology in the T\textsubscript{H}17 EAE model, as demonstrated by reduced weight loss and clinical score, with overall less advanced disease as compared to Maf\textsuperscript{fl/fl} control mice (Fig. 2f). Our findings thus demonstrate that the disease-associated pathology resulting from CD4-targeted Maf deletion phenocopies that of IL-10 deficiency in malaria and is in keeping with IL-10’s regulatory role in allergy. In contrast, Maf deletion in the EAE setting showed the opposite effect to that reported for IL-10 (ref. 30), indicating that c-Maf plays an additional role in T\textsubscript{H}17 responses that contributes towards pathology.

**Deciphering c-Maf-driven transcriptional programs within dominant disease-associated immune responses.** To better understand the disease-specific effects of Maf deletion, we performed RNA-seq on purified CD4\textsuperscript{+} T cells isolated from spleens, lungs and the central nervous system from the three disease models. Hierarchical clustering
revealed that the strongest variations in gene expression were driven by each disease (Fig. 3a and Supplementary Data for Computational Methods). However, a clear separation in gene expression in CD4^+ T cells from CD4-targeted Maf deleted mice versus controls, was not discernible, except in the malaria model (Fig. 3a). Indeed, 78% of the variance captured by the first two singular value decomposition components, clustered the samples according to the disease-specific immune response as shown by biological pathway analyses (Fig. 3b, c and d; Supplementary Table 2). The fourth component, although accounting for only 3% of the variance (Fig. 3b, c, and d; Supplementary Table 2) segregated the samples according to Maf-deficiency, irrespective of the disease (Fig. 3b, and Fig. 3d, right-hand panel). This component was enriched for both down-regulated genes, including transcriptional regulators and immune response genes such as Il10, and up-regulated genes, such as genes with proliferative function, E2f1, Runx3 and Il2ra (Fig. 3d). Thus, although the immune response dominates over the deletion of Maf, c-Maf does contribute to a small but coherent change in gene expression across all three diseases in vivo that includes Il10, corroborating the in vitro findings.

**c-Maf regulates Il10 expression in CD4^+ T cells in vivo with wider disease-specific effects.** Subsequent comparison of differentially expressed genes showed only 48 overlapping genes, as compared to the overall sizable perturbation of 2,635 genes in malaria, 1,073 in HDM allergy and 265 in EAE, many of which were in fact disease-specific, and equally up- or down-regulated, in the absence of c-Maf (Fig. 4a; Supplementary Fig. 2; Supplementary Table 3 and Supplementary Data for Computational Methods). To further characterize the context-specific effects of Maf
deletion, the differentially expressed genes belonging to the TF, cytokine and membrane receptor families were interrogated in more detail (Fig. 4b-d; Supplementary Table 4). Twelve percent of the “immune response” genes had known c-Maf relationships. The majority of c-Maf accountable differences in the “non-immune” genes, observed predominantly in malaria, had not previously been recognized (Fig. 4b-d, red lines show known c-Maf interactions). These control general biological processes such as cell cycle (E2f1, E2f12, E2f17 and E2f18) or circadian rhythm (Bhlhe40)\textsuperscript{31}, but could nonetheless contribute to the net effect of c-Maf on the immune response.

**Il10** expression was significantly reduced in CD4\textsuperscript{+} T cells across all three diseases in the absence of c-Maf (Fig. 4a and Fig. 4e-g; Supplementary Fig. 2a), as we also demonstrated in IL-27 driven CD4\textsuperscript{+} T cells and T\textsubscript{H}17 cells in vitro (Supplementary Fig. 1a). Similarly, IL-10 protein production by T\textsubscript{H}1 and T\textsubscript{H}2 cells, was reduced in response to Maf deletion both in malaria and HDM allergy disease models respectively (Fig. 5a-d). In EAE, however, IL-10 protein was not detectable in CD4\textsuperscript{+} T cells, in keeping with the low levels of **Il10** mRNA observed in this model (Fig. 4g). Although having a uniform role on induction of IL-10, c-Maf showed differing effects on hallmark TFs and cytokines as previously demonstrated\textsuperscript{7,32,33}. In malaria, increased Tbx21 expression and IFN-\gamma protein (Fig. 4e; Fig. 5a and b) were observed in the absence of c-Maf, phenocopying the reported effect of **Il10**-deletion on T\textsubscript{H}1 responses\textsuperscript{26}. We observed decreased levels of T\textsubscript{H}2-associated genes, including **Il4** and **Il5** in HDM allergy in the absence of c-Maf (Fig. 4f). Furthermore, there was a preferential abrogation of IL-4-IL-10 double-producing cells by intracellular cytokine staining (Fig. 5c and d), in keeping with the increased pathology (Fig. 2e). T follicular helper (T\textsubscript{FH}) associated genes, including Bcl6 in the
malaria model, and Icos and Il21 in both the malaria and HDM allergy models were also decreased (Fig. 4b and c), in line with previous reports of c-Maf positively regulating T_{FH} cells\textsuperscript{34,35}. However, the increased pathology that we observe in the CD4-targeted c-Maf mice during an acute malaria response cannot be accounted for by decreased T_{FH} cells, since deletion of T_{FH} cells specifically in Bcl6\textsuperscript{fl/fl}Cd4-cre mice does not affect pathology in the acute phase of malaria (Supplementary Fig. 3a), but only the parasitemia in the chronic phase\textsuperscript{36}. Moreover, we show also that IL-10, even as late as 15 days post infection, is primarily produced by non-T_{FH} cells (Supplementary Fig. 3b). In the EAE model, the T_{H17} associated genes (Rorc, Il17a and Il23r) (Fig. 4d and g) and IL-17A protein were decreased in the absence of c-Maf (Fig. 5d and e). We found that in the EAE model, this decrease in the T_{H17} response was accompanied by increased Foxp3 mRNA expression (Fig. 4g) and increased numbers of Foxp3\textsuperscript{+} T_{reg} cells in the absence of c-Maf (Fig. 5d and e). Collectively, our findings show that in addition to controlling T_{H1} and T_{H2} responses, c-Maf plays a novel, more dominant role in EAE, over-and-above IL-10 expression, by regulating the balance of T_{H17} (Rorc) and Foxp3\textsuperscript{+} T_{reg} cell responses, explaining the discordant disease susceptibility.

**The context specificity of c-Maf on the immune response is driven by both direct and indirect mechanisms.** To identify the molecular mechanisms whereby c-Maf affects gene regulation in CD4\textsuperscript{+} T cells in vivo, we used Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) to reveal functionally active genomic regions. Consistent with the RNA-seq profile (Fig. 3a), hierarchical clustering of ATAC-seq data revealed that the open chromatin landscape was dominantly driven by each disease, and
that a clear separation of chromatin accessibility between control and Maf-deficient CD4$^+$ T cells was only observed in the malaria model (Fig. 6a). This could potentially be explained by increased chromatin accessibility in the $Maf^{fl/fl}Cd4$-cre condition (Fig. 6b), partially explaining the larger number of dysregulated genes in this model (Fig. 4a). Although c-Maf does not itself show evidence of inducing chromatin remodeling (Fig. 6b), de novo motif discovery using MEME-ChIP$^{37}$ revealed Runx as being enriched in the remodeled loci, suggesting that Runx factors could account for increased open chromatin in malaria through their known interactions with epigenetic modifiers$^{38}$. However, these changes in chromatin accessibility are not exclusively responsible for the transcriptional changes observed by RNA-seq, since only a small fraction of the differentially expressed genes were associated with altered ATAC-seq peaks in any of the models (Supplementary Fig. 4). Taken together, these data indicate that c-Maf acts via activation and repression of gene expression and the context-specific action is defined by the accessible chromatin landscape dictated by the type of immune response.

We further integrated our RNA-seq and ATAC-seq data with c-Maf ChIP-seq$^7$ and motif data to identify c-Maf target genes, which were corroborated using the Binding and Expression Target Analysis (BETA) software$^{39}$ (Supplementary Fig. 5; Supplementary Table 5 and Supplementary Data for Computational Methods). Putative c-Maf binding sites were found to be enriched in differentially expressed genes, indicating that c-Maf can have direct effects and is responsible for the significant transcriptional changes seen (Supplementary Table 6). Specifically, the combined evidence of open chromatin coinciding with c-Maf binding to the $Il10$ locus confirmed c-Maf as a direct positive regulator of $Il10$ in vivo (Fig. 6c and d). However, although we found $Il4$ and
Rorc to also be direct targets of c-Maf, the effect of c-Maf on the expression of Tbx21 and Foxp3 was indirect with no evidence of direct binding to these loci (Fig. 6c and d; Supplementary Fig. 6). Thus, the observed changes in Rorc vs Foxp3 expression resulting from c-Maf deficiency are likely due to indirect mechanisms.

**IL-2 is a c-Maf target.** To identify candidate TFs responsible for the indirect effects of c-Maf, we applied the bivariate genomic footprinting (BaGFoot) software\textsuperscript{40} to the ATAC-seq data to assess changes in global TF activity, as measured by changes in TF footprint depth and motif flanking accessibility (Fig. 7a; Supplementary Table 7). TF binding site motifs that were significant outliers from the multivariate distribution, presenting differential TF binding in absence of c-Maf compared to control, were predominantly context-specific and more abundant in malaria, than HDM and EAE (Fig. 7a), in line with the expression data (Fig. 4a). Moreover, most of these TF motifs were found to be significantly enriched in the accessible genomic neighbourhood of differentially expressed over the non-differentially expressed genes (Supplementary Table 8) in the different diseases upon c-Maf deletion. The Runx TF, whose motif was enriched in the remodeled loci (Fig. 6b), showed enhanced binding (Fig. 7a) and increased expression (Fig. 3a; 4b-d and Supplementary Table 3) in Maf\textsuperscript{fl/fl} Cd4-cre mice exclusively in the malaria model. Further, it showed a more significant effect on differentially expressed genes than c-Maf itself (Supplementary Table 8). Thus, Runx may contribute to the increased pathology in malaria by its reported effects on IFN-\(\gamma\) production\textsuperscript{41}. The AP-1 family members BATF, Jund, Jun, and Junb (Fig. 7a; Supplementary Table 8), which are known to directly interact with c-Maf\textsuperscript{42}, may further contribute to changes in gene
expression, including *Il10* gene regulation\(^9\). *Bhlhe40*, a known negative regulator of IL-10 (ref. \(^{43}\)), which we found to be upregulated in *Maf*-deficient CD4\(^+\) T cells (Supplementary Table 3), also appeared to additionally contribute to the indirect effects of c-Maf in malaria and HDM allergy as shown by the BaGFoot analysis (Fig. 7a; Supplementary Table 8).

In contrast to the context-specific effects on TFs, the Nfat2 motif showed statistically significant differences in the genome-wide footprints (Fig. 7b) and contributed towards changes in gene expression in all three disease models (Fig. 7a; Supplementary Table 8). Based on the well-known role of NFAT in the regulation of *Il2* expression\(^{44}\), we now show that both *Il2* and *Il2ra* are potential direct targets of c-Maf (Fig. 7c). Since IL-2 is known to regulate Foxp3\(^+\) T\(_{reg}\) cells\(^{5,45}\) and T\(_{H17}\) (ref. \(^{46}\)) cells, we postulated that the observed increase in Foxp3\(^+\) T\(_{reg}\) and decreased T\(_{H17}\) cells in EAE (Fig. 4g and Fig. 5d and e) could result from indirect effects of c-Maf on IL-2. To test this and validate the results from our genome network analysis, the effect of c-Maf deletion on *Il2* expression was investigated. *Maf*-deficient CD4\(^+\) T cells expressed higher levels of *Il2* mRNA as compared to controls under all differentiation conditions, accompanied by a reciprocal decrease in *Rorc* and an increase in Foxp3 expression under T\(_{H17}\) and induced T\(_{reg}\) cell (iT\(_{reg}\) cell) conditions in vitro, respectively (Fig. 7d). Decreased levels of *Rorc* observed in *Maf*-deficient T\(_{H17}\) cells were indirect via the action of IL-2, since this effect was abrogated upon neutralization of IL-2 (Fig. 7d), resolving previously reported findings which suggested that c-Maf negatively regulates gene expression during T\(_{H17}\) differentiation\(^7\).
**Discussion**

Here we combined comprehensive transcriptional, epigenomic and TF binding analyses of CD4⁺ T cells from CD4-targeted Maf-deficient mice to show that c-Maf provides a common mechanism for direct transcriptional regulation of Il10 gene expression in CD4⁺ T cells in vivo in models of TH1, TH2, and TH17 responses. Furthermore, we identified a broad context-specific gene expression program regulated by c-Maf, over-and-above its effects on IL-10, which explained the unexpected diverse effects on each disease phenotype. We demonstrated that c-Maf in fact functions by both direct and indirect mechanisms to regulate gene expression and control the effector phenotype in TH1 and TH2 responses which, in conjunction with IL-10, may reinforce the distinct disease outcomes observed.

In malaria, TH1-associated genes are regulated indirectly by a c-Maf-driven gene network that reinforces TH1 cell behavior to combat pathology. For example, Bhlhe40, a gene associated with circadian rhythm\(^{31}\) as well as negative regulation of IL-10 (ref. \(^{43}\)), and Runx3, which is key for maximal production of IFN-\(\gamma\)\(^{41}\) in TH1 cells, were found to be upregulated and have increased activity in the absence of c-Maf. In contrast, we found that TH2-associated genes are direct targets of c-Maf, in keeping with its earlier definition as a positive regulator of TH2 cytokine gene expression\(^{32}\). However, c-Maf co-regulated IL-10 together with TH2-associated genes, thus the decreased IL-4, IL-10 double-producing TH2 cells observed in the absence of c-Maf may account for the overall detrimental effect on the disease pathology in the HDM allergy model.

While deletion of c-Maf resulted in increased susceptibility to disease in both the malaria and HDM allergy models, the severity of disease was decreased in EAE despite
reduced *Il10* expression, indicative of additional c-Maf regulated effects. Further inference of c-Maf regulatory networks showed that a proportion of the transcriptional changes seen could be a result of increased NFAT activity observed in *Maf*-deficient CD4+ T cells across all disease models. Based on the well-known role of NFAT in the regulation of *Il2* expression44, and our findings that both Il2 and Il2ra are direct c-Maf targets, we validated the predictions of the regulatory networks to demonstrate the role of c-Maf as a negative regulator of IL-2. Collectively our findings suggest that by negatively regulating *Il2* gene expression, c-Maf will have overarching context-specific effects on immune responses, on the one hand, limiting Th1 and Th2 responses which depend strongly on IL-2, on the other hand allowing the development of a Th17 response by regulating Rorc expression and Foxp3+ Treg cells. These findings are in apparent contrast to the recent studies using Foxp3-targeted deletion of c-Maf that resulted in reduced Rorc+Foxp3+ Treg cells19,20, which by nature of the system could not reveal the more global effects of c-Maf on gene expression in CD4+ T cells during distinct immune responses, that we herein report. Regardless, they reinforce our concept that c-Maf has context-specific effects on the immune response.

Taken together our findings demonstrate that c-Maf has a broad yet context-specific role in regulating gene expression allowing each type of T effector immune response to occur in a controlled yet effective manner. Our study also highlights the utility of genome-wide analyses that span multiple layers of transcriptional regulation to reveal and validate gene networks.
Figure legends:

Figure 1: The transcription factor Maf correlates with II10 expression in all TH and Treg cell subsets.

a. Representative cytokine staining of naive CD4+ T cells, in vitro differentiated TH0, TH0+block, TH1, TH1+IL-27, TH2, TH17, VitD3+Dex CD4+ T cell subsets (n=2 independent experiments each) and of Treg cells ex vivo (n=3 independent experiments).

b. CD4+ T cells from (a) were profiled by RNA-seq. Heatmap showing the mean gene expression levels (12,742 genes) of naive CD4+ T cells (n=2 independent experiments, one of which with 3 culture wells), in vitro differentiated TH0 (n=2 independent experiments), TH0+block (n=2 independent experiments, 3 culture wells each), TH1 (n=2 independent experiments), TH1+IL-27 (n=2 independent experiments), TH2 (n=2 independent experiments), TH17 (n=2 independent experiments, 3 culture wells each), VitD3+Dex (n=2 independent experiments) after culture (0h) or following a 0.5, 2 and 6h re-stimulation in vitro and of Treg cells ex vivo, either Foxp3RFP+ IL-10GFP+ or IL-10GFP- (n=3 independent experiments each). c, d Expression of II10 (mean±SD) (c) and of hallmark cytokines at 6h post restimulation (d, values represent log2 of the mean expression value per population) in the different CD4+ T cell populations from (b). e, Transcription factors positively and negatively correlating with the expression of II10 across all the different CD4+ T cell populations from (b) (Pearson correlation, transcription factors previously associated with IL-10 highlighted in black). f, Linear regression of II10 and hallmark cytokines vs Maf or TH subset master regulators (symbols represent the mean read counts per CD4+ T cell subset per timepoint from (b), shaded area 95% CI).
Figure 2: c-Maf deficiency in CD4+ T cells affects susceptibility to disease in a context-specific manner.

a-c, Schematics of *P. chabaudi* infection, HDM allergy and EAE disease models performed in *Maf*0/0 and *Maf*0/0*Cd4*-cre mice. d, Weight loss, temperature and parasitemia during *P. chabaudi* infection (n=14, mean±SEM). e, Total cell and differential Giemsa-stained eosinophil counts from BAL upon HDM challenge (n=5, mean±SD), representative lung sections and cumulative total inflammation (H&E) and mucous (AB-PAS) scores (*, *P* < 0.05 Mann-Whitney, two-tailed). f, Weight loss and clinical score (including linear regression *, *P* ≤ 0.035 F-test) during EAE (n=10, mean±SEM), distribution of disease severity (no EAE = score < 2, mild EAE = score 2-3, severe EAE > score 4, n=28). Representative data from three biological experiments per disease model are shown.
Figure 3: Deciphering c-Maf driven transcriptional programmes within dominant disease-associated immune responses.

CD4+ T cells from malaria, HDM and EAE challenged Maf^{fl/fl} Cd4-cre and Maf^{fl/fl} mice were profiled by RNA-seq. a, Unsupervised hierarchical clustering heatmap showing the Spearman correlation of the mean gene expression levels between the different diseases and mice. b, Singular value decomposition (SVD) was used to identify major sources of gene expression variation between malaria, HDM and EAE challenged Maf^{fl/fl} Cd4-cre and Maf^{fl/fl} mice (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype); analyses of variance (ANOVA; shown as -log P-value of the chi-squared test) and the Akaike Information Criterion (AIC) were then used to test the association of each component with the disease and/or strain. c, Scatter plot showing the relative separation between malaria, HDM and EAE challenged Maf^{fl/fl} Cd4-cre and Maf^{fl/fl} mice (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype) along components 1, 2 and 4. d, (Upper left) Bar plots showing the average right singular vectors for components 1, 2 and 4 for each condition (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype, mean±SEM); (upper right) heatmaps displaying the expression levels of the most positively (dark grey box) and negatively (light grey box) contributing and correlating genes with the right singular vectors of the corresponding component; (lower) lists of top biological pathways and example genes by GO enrichment analysis of each component (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype).
Figure 4: c-Maf regulates *Il10* expression in CD4$^+$ T cells in vivo with wider disease-specific effects. 

a, Venn diagrams showing the overlap of differentially expressed, up- and down-regulated genes in CD4$^+$ T cells from malaria, HDM allergy and EAE challenged *Maf$^{fl/fl}$Cd4-cre* vs *Maf$^{fl/fl}$* mice (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype; $P < 0.05$, absolute FC $\geq 1.5$, moderated *t*-test, two-tailed).

b-d, Networks of differentially expressed transcription factor, cytokine and trans-membrane receptor genes (blue, down-regulated; red, up-regulated; size of symbol, mean read number; red lines, known c-Maf interactions).

e-g, Normalized read counts of selected T$_H$ cell master regulator transcription factors and hallmark cytokines in CD4$^+$ T cells from malaria, HDM allergy and EAE challenged mice (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype, mean±SD; *, $P < 0.05$, absolute FC $\geq 1.5$, moderated *t*-test, two-tailed; BT, below filtering threshold).
Figure 5: c-Maf deficiency results in the loss of IL-10 secreting effector T\textsubscript{H}1 and T\textsubscript{H}2 cells in malaria and HDM allergy disease models, whilst in EAE c-Maf plays a dominant role in controlling the T\textsubscript{H}17/T\textsubscript{reg} cell balance.

a, c, e, Representative cytokine staining of CD4\textsuperscript{+} T cells from malaria (spleen), HDM allergy (lung) and EAE (spinal cord) challenged Maf\textsuperscript{fl/fl}Cd4-cre and Maf\textsuperscript{fl/fl} mice gated on live CD4\textsuperscript{+} (CD4\textsuperscript{+}CD44\textsuperscript{+}, HDM) T cells. b, d, f, Representative box plots (box limits are at the 25-75 centiles, centre line represents the median and whiskers represent the minimum and maximum values) of percentages (top row) and numbers (bottom row) of cytokine-secreting CD4\textsuperscript{+} T cells from malaria (n=5), HDM allergy (n=5) and EAE (n=10) disease models (*, P < 0.05, unpaired t-test, two-tailed) Representative data from three biological experiments are shown.
Figure 6: The context specificity of c-Maf on the immune response is driven by both direct and indirect mechanisms.

a, Heatmap showing the Spearman correlation between read coverages underlying ATAC-seq peaks called in CD4⁺ T cells from malaria, HDM and EAE challenged Maf⁰/⁰Cd4-cre and Maf⁰/⁰ mice profiled by ATAC-seq (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype). b, Volcano plots of changes in ATAC-seq consensus peak sets between Maf⁰/⁰Cd4-cre and Maf⁰/⁰ (statistical significance called using DiffBind 2.02 with FDR < 0.05, absolute fold change ≥ 1.5); top 10 peaks ranked by fold-change are labelled with the assigned target gene, as well as those peaks assigned to Il10. De novo motif discovery identified the Runx TF family motif as the top match in differentially accessible ATAC-seq peaks in the malaria model (MEME-ChIP, E-value 3.8e-92). c, Heatmaps for differentially expressed genes indicating the presence of ATAC-seq peaks with overlapping c-Maf ChIP-seq occupancy and/or c-Maf motif matches (called direct targets, black bracket), or neither (indirect targets, orange bracket). Putative direct and indirect targets are further corroborated using the BETA software with high scores representing greater likelihood of direct regulation. d, Genome browser tracks of read coverage of RNA-seq and ATAC-seq in CD4⁺ T cells from the different disease models (shown as an overlay of n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype) as compared to untreated control and matched to c-Maf ChIP-seq and motif sites.
Figure 7: Identification and validation of IL-2 as a c-Maf target from inferred c-Maf regulated TF networks.

a, Bagplots depicting TFs with potential genome-wide changes in binding between CD4+ Maffl/fl and Maff Cd4-cre within ATAC-seq peaks in CD4+ T cells, as detected using the BaGfoot software. P-values in the key of the figure refer to the statistical confidence assigned to the differential binding of a TF in each disease model (n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype), see Supplementary Data). Labelled in bold are TFs whose motif is enriched in the accessible genomic neighbourhood of differentially expressed genes (one-tailed Fisher’s exact test q-value < 0.05).

b, Metaprofiles of ATAC-seq footprints containing an Nfatc2 motif match, in CD4+ Maffl/fl and Maff Cd4-cre T cells from malaria (yellow/orange), HDM allergy (light/dark green) and EAE (light/dark blue). Coloured dashed lines represent the sum of Tn5 insertions across the footprint region in each condition. Vertical dashed lines represent the motif boundaries.

c, Genome browser tracks of read coverage of RNA-seq and ATAC-seq in CD4+ T cells from the different disease models (shown as an overlay of n=3 independent animals (malaria) or biologically independent samples (HDM and EAE) per genotype) as compared to untreated control and matched to c-Maf ChIP-seq and motif sites.

d, Naive CD4+ T cells from Maffl/fl and Maff Cd4-cre mice were differentiated in vitro and assessed for the expression of Il2, Rorc and Foxp3 relative to Hprt (mean±SD; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, unpaired t-test, two-tailed); T17 cells were differentiated in vitro and assessed for the expression of Rorc in the presence or absence of anti-IL-2 (n=3 culture wells per condition, mean±SD; * P < 0.05, one-way ANOVA). Representative data from three (or two, Th2) independent experiments are shown.
Data Availability
The materials, data, code and any associated protocols that support the findings of this study are available from the corresponding author upon request. The RNA-seq and ATAC-seq data sets have been deposited in the Gene Expression Omnibus database under accession number GSE106464.

Supplementary Data
Supplementary data is linked to the online version of the paper at www.nature.com/nature.

Acknowledgments
We thank The Francis Crick Institute, Biological Services for breeding and maintenance of the mice; the Advanced Sequencing Platform and A. Sesay for help with sequence sample processing; the Flow Cytometry Platform; Bioinformatics Platform, G. Kelly; and Photographics, M. Butt; for assistance. We thank V. Stavropoulos for help with in vivo experiments. We thank A. Singhania and L. Moreira-Teixeira from the AOG laboratory at the Francis Crick Institute for careful review and discussion of the manuscript. AOG, LG, KP, MA, LSC, CW and work of this work of AOG was supported by the Francis Crick Institute (Crick Core), which receives its core funding from Cancer Research UK (FC001126, FC010110), the UK Medical Research Council (FC001126, FC010110), and the Wellcome Trust (FC001126, FC010110) since 1st April 2015 and before that by the UK Medical Research Council (MRC U117565642) and also by the European Research Council grant 294682-TB-PATH (Crick 10127). L.G. was additionally funded by an MRC Centenary Award. JL was funded by the Crick Core project code 10101; JB and VM were funded by the Crick Core project FC001051 and by the Wellcome Trust WT098326MA. N.M.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support towards the establishment of The Francis Crick Institute. N.L. is additionally funded by a Wellcome Trust Joint Investigator Award (103760/Z/14/Z), and the MRC eMedLab Medical Bioinformatics Infrastructure Award (MR/L016311/1). M.H.S is a Berlin Institute of Health–Einstein visiting fellow and supported by Inserm, CNRS (ANR-11-BSV3-0026) (DEQ. 20110421320), ERC 695093.

Author Contributions
L.G. co-designed the study, executed the experiments and interpreted and analyzed the data and co-wrote the paper; M.A.M. analyzed the ATAC-seq, ChIP-seq and RNA-seq data and contributed towards the writing of the paper; R.L. interpreted and analyzed the RNA-seq data and contributed towards writing of the paper; L.S.C. executed and helped design the in vitro experiments with c-Maf-deficient CD4+ T cells and controls, and analyzed the data; J.S. and C.H. helped execute and interpret malaria experiments; D.P-M. contributed data for Supplementary Figure 3; C.W. helped execute EAE experiments; Y.K. and M.W. helped execute and interpret allergy experiments; K.P. performed early RNA-seq analysis; X.W. executed the genetics for obtaining Cδ4-cre x Maffl/fl mice and designed, performed all screening and quality control; L.B. performed processed and trouble-shooting for RNA-seq; H.W. constructed Maffl mice and provided feedback on the study; M.H.S. provided feedback and suggestions for the study; G.E. supervised early RNA-seq data analysis; J.L. provided the malaria model expertise and feedback on the
study; V.M. and J.B. provided expert advice and input on the ATAC-seq analysis; N.M.L. provided expert advice and input on the RNA-seq analysis and directed the integrated analysis of ATAC-seq, ChIP-seq and RNA-seq; A.O.G. co-designed the study, interpreted and analyzed the data and co-wrote the paper.

Author information
Reprints and permissions information is available at www.nature.com/reprints. The author(s) declare no competing financial interests. Correspondence and requests for materials should be addressed to Anne.OGarra@crick.ac.uk.

Competing financial interests
The authors declare no competing financial interests.
References


Bettelli, E. et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. *J. Immunol.* **161**, 3299-3306 (1998).


**Materials and methods:**

**Animals.** All mice were bred and maintained under specific pathogen-free conditions at The Francis Crick Institute, Mill Hill laboratory according to the Home Office UK Animals (Scientific Procedures) Act 1986 and used mostly at 8–12 weeks of age. C57BL/6/J wild-type mice were bred in-house. Foxp3RFP IL-10GFP were provided by RA Flavell\(^{18,47}\). *Maf\(^{fl/fl}\)* mice provided by M. Sieweke and C. Birchmeier (Max Delbrück Centre for Molecular Medicine, Germany)\(^{48}\), were backcrossed to C57Bl/6/J mice for ten generations and subsequently crossed to *Cd4-cre*\(^{49}\) to generate *Maf\(^{fl/fl}\)Cd4-cre* mice, with *Maf\(^{fl/fl}\)* mice used as controls. *Bcl6\(^{fl/fl}\)* (ref. 50) were crossed to *Cd4-cre* to generate *Bcl6\(^{fl/fl}\)Cd4-cre* mice. All animal experiments were carried out in accordance with UK Home Office regulations (project licenses: malaria, 80/2358; HDM allergy, 80/2506; EAE, 70/7643) and were approved by The Francis Crick Institute Ethical Review Panel.

**T cell sorting and in vitro T\(_h\) cell differentiation.** Naive CD4\(^+\)CD62L\(^+\)CD44\(^lo\)CD25\(^-\) T cells were purified from mouse spleens following negative enrichment of CD4\(^+\) T cells and sorted on a MoFlo\(^\text{TM}\) XDP cytometer (Beckman Coulter) using CD4 (RM4-5) e450, CD62L (MRL-14) PE-Cy7, CD44 (IM7) PE and CD25 (PC61.5) APC antibodies (all eBioscience) to over 95% purity. Sorted T cells at 5 × 10\(^5\) per well in flat-bottom 48-well plates were activated with plate-bound anti-CD3 (2 \(\mu\)g/ml, 145-2C11, Harlan) and anti-CD28 (10 \(\mu\)g/ml, 37.51, Harlan) and cultured in IMDM (T\(_h\)17) or with anti-CD3 (5 \(\mu\)g/ml) and soluble anti-CD28 (2 \(\mu\)g/ml) and cultured in RPMI (other cell types) and cultured under the following conditions for 7 days unless otherwise stated. T\(_h\)0+block: anti-IL-12p40 (C17.8.20, gift from G. Trinchieri, Wistar Institute, USA), anti-IFN-\(\gamma\) (XMG1.2, Harlan), anti-IL-4 (11.B.11, gift from DNAX), anti-IL-6 (MP5-20F3, gift from DNAX) and anti-TGF-\(\beta\) (1D11.16, gift from DNAX) at 10 \(\mu\)g/ml. T\(_h\)0: no cytokines or blocking antibodies were added. T\(_h\)1 (+IL-27): rmIL-12p70 (5 ng/ml, Biolegend) and anti-IL-4 with or without (rmIL-27, 20ng/ml, R&D Systems). T\(_h\)2: rmIL-4 (10 ng/ml; R&D Systems), IL-2 (5 ng/ml; Insight Biotechnology), anti-IL-12p40 and anti-IFN-\(\gamma\). T\(_h\)17: rhTGF-\(\beta\)1 (2 ng/ml, R&D Systems), rhIL-6 (50 ng/ml, R&D Systems) and anti-IFN-\(\gamma\), anti-IL-4 and anti-IL-12 for 5 days. VitD3+Dex: Vitamin D3 (4x10\(^{-8}\)M, Enzo Life
Sciences), Dexamethasone (1x10^8M, Sigma-Aldrich) anti-IL-4, anti-IFN-γ, anti-IL-12 for 21 days. T_reg cells: CD4+ (CD4 APCe780, eBioscience) Foxp3RFP^IL-10GFP^- or Foxp3RFP^IL-10GFP^+ were sorted directly ex vivo.

For RNA, cells were either taken at the end of the culture (0 hour), or re-stimulated with anti-CD3 and anti-CD28 at 2 µg/ml each for 0.5, 2 and 6 hours. Two (Naïve, T_H0, T_H0+block, T_H1, T_H1+IL-27, T_H2, T_H17, VitD3+Dex; for each biological replicate, RNA was pooled from technical triplicates unless otherwise stated) or three (IL-10^+ vs IL-10^- T_reg cells) independent biological experiments were performed. To assess the effect of c-Maf on CD4^+ T cells differentiation in vitro, naive Maf^fl/fl Cd4-cre vs Maf^fl/ft CD4^+ T cells were sorted and stimulated with anti-CD3 and anti-CD28 (5/2 µg/ml respectively - medium alone, 5 ng/ml IL-12, 25ng/ml IL-27, IL-12+IL-27, 10 ng/ml IL-4, 50 ng/ml IL-21 or IL-4+IL21 in RPMI; 2/10 µg/ml respectively - 0.5ng/ml TGF-β alone or with 2ng/ml TGF-β and 50ng/ml IL-6 plus or minus 10 µg/ml anti-IL-2 (JES6-1A12, Bio X Cell) in IMDM) for up to 5 days.

**Disease models. Malaria:** Mice (male) housed under reverse light were infected intraperitoneally with 10^5 Plasmodium chabaudi chabaudi AS infected red blood cells (RBC). Blood smears were taken daily (am) when parasite sequestration is low in order to best estimate the level of parasitemia, the proportion of parasitized RBCs were monitored as described previously^51^. Measurements of clinical pathology, body weight and temperature (measured using a non-invasive thermometer, Fluke), were also taken daily (pm) and calculated relative to the day 0 baseline. For RNA-seq and ATAC-seq, T cells were enriched by negative selection from individual spleens (3 mice each Maf^fl/fl and Maf^fl/ft-Cd4-cre) on day 7 post infection as described above and Ter119CD3CD4^+ T cells (Ter119 (TER-119) APCCy7, BD; CD3 (145-2C11) APC, CD4 (RM4-5) e450, eBioscience) were sorted on MoFlo™ XDP or BD Fusion cytometer. **House dust mite (HDM)-induced airway allergy.** Mice (female) were sensitized with 10 mg HDM (Greer) or PBS and 2mg Imject Alum (Thermo Scientific) by intraperitoneal injections on days 0 and 14, and challenged intratracheally with 10 mg HDM or PBS on days 21 and 24 as described previously^29^. On day 25, bronchoalveolar lavage was preformed and differential cell counts obtained following Cytospin and staining with Accustain Wright-
Giemsa (Sigma-Aldrich). For histology, left lung lobes were fixed in 4% formaldehyde followed by 70% ethanol and stained with hematoxylin and eosin (inflammation) and Alcian blue/periodic acid–Schiff (mucus). Sections were scored for inflammation and mucus on a 0-4 scale as described<sup>28</sup>, except the average score of all individual airways was calculated. For RNA-seq and ATAC-seq, CD4<sup>+</sup> T cells were enriched by positive selection (Miltenyi Biotech) from perfused lungs on day 25 (pooled from at least 5 Maf<sup>fl/fl</sup> or Maf<sup>fl/fl</sup>Cd4-cre mice and three biological replicates were performed) following a Percoll gradient separation and CD3-CD4-CD44<sup>+</sup> (CD3<sup>145-2C11</sup> APC, CD4<sup>RM4-5</sup> e450 and CD44<sup>IM7</sup> PE, eBioscience) T cells were sorted on MoFlo<sup>TM</sup> XDP cytometer.

**Experimental autoimmune encephalomyelitis (EAE).** EAE was induced by immunizing mice (male or female) subcutaneously with 250 µg MOG<sub>35-55</sub> peptide (Cambridge Research Biochemicals) emulsified in complete Freund’s adjuvant containing 250 µg heat-killed M. tuberculosis H37RA (Difco Laboratories) on day 0. On days 0 and 2 post immunization, mice received 200ng pertussis toxin (Calbiochem) intraperitoneally. Measurements of clinical pathology (body weight and clinical score) were taken daily and calculated relative to the day 0 baseline. Disease severity scoring: no paralysis, 0; flaccid tail, 1; impaired righting reflex and/or gait, 2; partial hind limb paralysis, 3; complete hind limb paralysis, 4. For RNA-seq and ATAC-seq, CNS cells were enriched by Percoll gradient from perfused brains and spinal cords (pooled from at least 10 Maf<sup>fl/fl</sup> or Maf<sup>fl/fl</sup>Cd4-cre mice and three biological replicates were performed) on day 14-16 post immunization and CD45.2<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup> (CD45.2<sup>104</sup> APC, CD4<sup>RM4-5</sup> e450, CD4<sup>RM4-5</sup> PE) T cells were sorted on MoFlo<sup>TM</sup> XDP cytometer. For RNA-seq (Maf<sup>fl/fl</sup>) and ATAC-seq (C57BL/6) on untreated CD4<sup>+</sup> T cells, CD4<sup>+</sup> T cells were purified from mouse spleens following negative enrichment and CD3-CD4<sup>+</sup> T cells (CD3<sup>145-2C11</sup> APC, CD4<sup>RM4-5</sup> e450) were sorted on MoFlo<sup>TM</sup> XDP cytometer.

**Flow cytometry and intracellular cytokine and transcription factor staining of in vitro differentiated T<sub>H</sub> cells.** After differentiation, T cells were re-stimulated with anti-CD3 and anti-CD28 at 2 µg/ml each or PDBU (Sigma-Aldrich) and Ionomycin (Calbiochem) at 500 ng/ml each (T<sub>H</sub>17) for 4 hours, with Brefeldin A (10 µg/ml, Sigma-Aldrich) added for the last 2 and 4 hours of culture, respectively. Surface markers were
stained in PBS together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). For intracellular cytokine detection, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer (eBioscience) and stained with: anti-IL-2 (JES-5H4) APC-Cy7 (BD), anti-IFN-γ (XMG1.2) PE-Cy7 (BD) and anti-IL-4 (11B11) PE, anti-IL-10 (JES5-16E3) APC, anti-IL17A (eBi17B7) FITC (eBioscience). For Foxp3 and c-Maf staining, cells were fixed with Fixation/Permeabilization buffers and stained with Foxp3 (FJK-16S) PE or c-Maf PerCP-eFluor (symOF1) 710 with IgG2bK isotype (BMG2b) eFluor 710 control (eBioscience). Intracellular cytokine staining of ex vivo cells. Malaria: spleen cells were isolated on day 12 post infection and restimulated with 50 ng/ml PMA and 500 ng/ml Ionomycin (Sigma-Aldrich) for 4 hours, with Golgi Plug (BD) added for the last 2 hours of culture. Cells were then pretreated with anti-CD16/32 (2.4G2) (BD) and surface stained in PBS with CD4 (RM4-5) BV605, CD8 (53-6.7) BV650, CD3 (145-2C11) APC-Cy7 and Zombie Aqua (Biolegend). After surface staining, cells were fixed with Fixation buffer followed by permeabilization in Perm Buffer (Biolegend) and stained intracellularly with IL-10 (JES5-16E3) FITC and IFN-γ (XMG1.2) PE-Cy7 (eBioscience). T_{FH} cell staining was carried out as previously described. HDM: lung cells were isolated from the right lower lobe on day 25 using Percoll and restimulated with 50 ng/ml PMA and 1 mg/ml Ionomycin (Sigma-Aldrich) and Golgi Stop and Plug (BD) for 6 hours. Cell were then surface stained in PBS with CD3 (17A2) e780, CD4 (RM4-5) e450, CD44 (1M7) PerCpCy5.5 (eBioscience) in the presence of anti-CD16/32 (2.4G2) together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). After surface staining, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer and stained intracellularly with IL-4 (11B11) PE-Cy7 and IL-10 (JES5-16E3) APC (eBioscience). EAE: cells were isolated from spinal cords and brains on day 16 post immunization using Percoll and restimulated with 50ng/ml PMA and 500 ng/ml Ionomycin for 4 hours, with Brefeldin A (10 µg/ml, Sigma-Aldrich) added for the last 3 hours of culture. Cells were then pretreated with anti-CD16/32 (10 µg/ml, Harlan) and surface stained in PBS with CD45.2 (104) PE (eBioscience), CD3 (17A2) BV785 and CD4 (RM4-5) BV605 (Biolegend) together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). After surface staining, cells were fixed with intranuclear Fixation/Permeabilization buffers.
(eBioscience) and stained with IL-17A (eBi17B7) FITC, Foxp3 (FJK-16S) PE (eBioscience) and IFN-γ (XMG1.2) PE-Cy7 (BD). Samples were acquired on LSR II or Fortessa (BD) and analyzed using Flow Jo software (Treestar).

**RNA extraction and pre-processing for RNA-seq.** RNA from in vitro and ex vivo CD4⁺ T cells was extracted using RNeasy Mini Kit according to the manufacturer’s instructions (Qiagen). RNA-seq libraries were made with TruSeq RNA Sample Preparation Kit V2 according to the manufacturer’s instructions (for EAE, SMARTer® Ultra™ Low Input RNA Kit – v3 was used to generate cDNA which were fragmented on Covaris at 200bp before generating libraries using NuGen Ovation ultralow kit) and sequenced using the HiSeq 2500 System with single-end read lengths of 50bp, depth 27-65M reads per sample (Illumina). Alignment of reads to the mouse transcriptome (mm10) and absolute quantification of the genes was performed in Strand NGS (version 2.0) with default parameters (95% identity, max 5% gaps, 1 read only if duplicated, ignoring reads with more than 5 matches), guided by RefSeq annotations (2013.04.01) (in vitro T_H cells and ex vivo T_reg) or Ensembl (2014.04.01) (ex vivo CD4⁺ T cells from malaria, HDM allergy and EAE). See Supplementary Data for further data processing.

**Quantitative RT-PCR.** RNA was extracted using RNAeasy microkit (Qiagen) and reverse transcribed into cDNA using as High Capacity Reverse Transcription kit (Applied Biosystems) according to manufacturer’s instructions, followed by RNaseH (Promega) treatment for 30 min at 37°C. cDNA was analyzed for the expression of the following factors on the 7900HT ABI or QS3 real-time PCR systems (Applied Biosystems) using TaqMan primer probes to mouse Maf, Mm 02581355_s1; Il10, Mm00439616_m1; Tbx21, Mm00450960_m1; Ifng, Mm01168134_m1; Gata3, Mm00484683_m1; Il4, Mm00445260_m1; Rorc, Mm01261019_g1 and Il17a, Mm00439619_m1, Foxp3, Mm 00475162_m1, Il2, Mm 00434256_m1 and Il2ra, Mm 01340213_m1 all from Applied Biosystems. The comparative threshold cycle method with Hrpt1, Mm03024075_m1 as an internal control was used for the normalization of target gene expression.
**ATAC-seq.** Samples were prepared as described previously\(^5\)\(^2\), with the transposition reaction carried out for 1h and 30 minutes at 37 °C and subsequent PCR amplification for 12 cycles. For EAE, 25,000 cells were used and the transposition reaction was scaled down accordingly, in a 25 µl reaction volume. See Supplementary Data for further data processing.

**Statistical Analysis**
GraphPad Prism Version 6 was used to perform experimental statistical analysis. The statistical significance of differences between data groups was determined by an unpaired, two-tailed Student’s t-test or two-tailed Mann-Whitney test where applicable at the 95% confidence level. For linear regression, correlation coefficients of determination and \(P\)-values were calculated using the mean value of biological replicates. All sequencing data analyses were performed with the R statistical package version 3.3.1 (2016) and Bioconductor libraries version 3.3\(^5\)\(^3\) unless otherwise stated (see Supplementary Data for more information). For exact \(n\) values and error bars used refer to individual figure legends.

**Data Availability**
The materials, data, code and any associated protocols that support the findings of this study are available from the corresponding author upon request. The RNA-seq and ATAC-seq data sets have been deposited in the Gene Expression Omnibus database under accession number GSE106464.
References


